@article{2d6a1fc538a94186b9dbc7264ae89569,
title = "Effectiveness of Levetiracetam Monotherapy in Pediatric Patients With Epilepsy",
abstract = "The main objective of this study was to assess the efficacy, safety, and retention rates of levetiracetam monotherapy in children with epilepsy. A retrospective review of pediatric patients receiving levetiracetam monotherapy at 2 large tertiary epilepsy centers over an 11-year period was conducted. One hundred two patients using levetiracetam monotherapy with a mean age of 13.1 years were identified. For the entire cohort, a 6-month retention rate was 61.1% and a 12-month retention rate 53.1%. With regard to seizure freedom, 46.8% of those patients that remained on monotherapy for at least 6 months became seizure free. Twelve-month seizure freedom was reached by 41.2%. About one-third (32.4%) of patients reported adverse effects, with irritability, moodiness, and depression being the most common. Despite a number of patients that reported adverse events, levetiracetam monotherapy was found to be potentially effective in this cohort of children with epilepsy and warrants further, prospective studies.",
keywords = "antiepileptic drug, efficacy, epilepsy, levetiracetam, pediatric",
author = "Mazur, {Rafal D.} and {Wang, BA}, Qianyu and {Kato, BS}, Kenneth and {Buchsbaum, BS}, Richard and {Bonito, BS}, Jennifer and Hyunmi Choi and Lawrence Hirsch and Kamil Detyniecki",
note = "Funding Information: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: LH reports honoraria, consultation fees, and/or speaker fees from Elan, GlaxoSmithKlein, Ortho-McNeil, Lundbeck, Esai, UCB Pharma, and Sunovion. HC reports research support from Acorda Therapeutics, Sunovion, Eisai, and Lundbeck. KD reports consultation fees from UCB, and research support from Acorda Therapeutics, Sunovion, Eisai and Lundbeck Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Columbia and Yale AED Database has been supported by Elan, GlaxoSmithKline, Ortho-McNeil, Lundbeck, Esai, UCB Pharma, and Sunovion. The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. Publisher Copyright: {\textcopyright} The Author(s) 2019.",
year = "2019",
month = sep,
day = "1",
doi = "10.1177/0883073819846804",
language = "English (US)",
volume = "34",
pages = "593--597",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "10",
}